ATE410167T1 - Flüssige pharmazeutische palonosetronformulierungen - Google Patents

Flüssige pharmazeutische palonosetronformulierungen

Info

Publication number
ATE410167T1
ATE410167T1 AT04706657T AT04706657T ATE410167T1 AT E410167 T1 ATE410167 T1 AT E410167T1 AT 04706657 T AT04706657 T AT 04706657T AT 04706657 T AT04706657 T AT 04706657T AT E410167 T1 ATE410167 T1 AT E410167T1
Authority
AT
Austria
Prior art keywords
liquid pharmaceutical
palonosetron formulations
palonosetron
formulations
pharmaceutical
Prior art date
Application number
AT04706657T
Other languages
English (en)
Inventor
Giorgio Calderari
Daniele Bonadeo
Roberta Cannella
Enrico Braglia
Riccardo Braglia
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32825409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE410167(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Application granted granted Critical
Publication of ATE410167T1 publication Critical patent/ATE410167T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
    • B65B55/02—Sterilising, e.g. of complete packages
AT04706657T 2003-01-30 2004-01-30 Flüssige pharmazeutische palonosetronformulierungen ATE410167T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44435103P 2003-01-30 2003-01-30

Publications (1)

Publication Number Publication Date
ATE410167T1 true ATE410167T1 (de) 2008-10-15

Family

ID=32825409

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04706657T ATE410167T1 (de) 2003-01-30 2004-01-30 Flüssige pharmazeutische palonosetronformulierungen

Country Status (41)

Country Link
US (9) US7947724B2 (de)
EP (2) EP2008659A1 (de)
JP (2) JP5461763B2 (de)
KR (1) KR101113084B1 (de)
CN (2) CN102813621A (de)
AP (1) AP2110A (de)
AR (1) AR042977A1 (de)
AT (1) ATE410167T1 (de)
AU (1) AU2004208505C1 (de)
BR (1) BRPI0407121B8 (de)
CA (5) CA2573194A1 (de)
CR (1) CR7921A (de)
CY (1) CY1108660T1 (de)
DE (1) DE602004016967D1 (de)
DK (1) DK1601359T3 (de)
EA (1) EA014066B1 (de)
EC (1) ECSP055938A (de)
ES (1) ES2315635T3 (de)
GE (1) GEP20084445B (de)
HK (1) HK1076401A1 (de)
HR (1) HRP20050676B1 (de)
IL (1) IL169859A (de)
IS (1) IS7984A (de)
JO (1) JO2735B1 (de)
MA (1) MA27710A1 (de)
MX (1) MXPA05008028A (de)
MY (1) MY144036A (de)
NO (1) NO329500B1 (de)
NZ (1) NZ541533A (de)
PA (1) PA8594801A1 (de)
PE (1) PE20050066A1 (de)
PL (1) PL378398A1 (de)
PT (1) PT1601359E (de)
RS (1) RS20050578A (de)
SI (1) SI1601359T1 (de)
TN (1) TNSN05180A1 (de)
TW (1) TWI342212B (de)
UA (1) UA90449C2 (de)
UY (1) UY28175A1 (de)
WO (1) WO2004067005A1 (de)
ZA (1) ZA200506917B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
CN100336508C (zh) * 2005-02-23 2007-09-12 重庆医药工业研究院有限责任公司 一种稳定的帕洛诺司琼注射液
CN100455286C (zh) * 2006-11-21 2009-01-28 深圳海创医药科技发展有限公司 帕洛诺司琼注射液及其制备方法
EP2164960A2 (de) 2007-05-25 2010-03-24 North Carolina State University Plattform zur zuführung von virusnanopartikeln an zielzellen
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
US20100143461A1 (en) 2008-12-08 2010-06-10 Ben-Zion Solomon Palonosetron formulation
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
CN102781939A (zh) 2009-11-13 2012-11-14 赫尔辛医疗股份公司 帕洛诺司琼代谢物
CN104856998A (zh) 2009-11-18 2015-08-26 赫尔辛医疗股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
EP2722045B1 (de) 2009-11-18 2016-07-06 Helsinn Healthcare SA Zusammensetzungen zur Behandlung von zentral vermitteltem Unwohlsein und Erbrechen
KR101368587B1 (ko) * 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
JP2014530249A (ja) 2011-10-18 2014-11-17 ヘルシン ヘルスケア ソシエテ アノニム ネツピタントおよびパロノセトロンの治療学的組合せ
EP3087987A4 (de) * 2013-12-23 2017-08-02 Samyang Biopharmaceuticals Corporation Pharmazeutische zusammensetzung mit einem palonosetron
CN104784107A (zh) * 2014-01-17 2015-07-22 南京瑞尔医药有限公司 一种盐酸托烷司琼口服液的制备方法
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
CA3025837C (en) * 2016-06-06 2024-02-13 Helsinn Healthcare Sa Physiologically balanced injectable formulations of fosnetupitant
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
JP6642377B2 (ja) * 2016-10-25 2020-02-05 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
EP3672964A4 (de) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. Neuartige dreifachkombinationsformulierungen für antiemetische therapie
SI3737378T1 (sl) * 2018-01-12 2023-06-30 Orion Corporation Kapljice palonosetrona za oči za zdravljenje ali preprečevanje slabosti in bruhanja
JP7090845B2 (ja) * 2018-08-03 2022-06-27 高田製薬株式会社 パロノセトロン含有液体組成物
JP7438802B2 (ja) 2020-03-23 2024-02-27 シオノギファーマ株式会社 パロノセトロン含有組成物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS599539B2 (ja) * 1979-11-13 1984-03-03 日本化薬株式会社 ニトログリセリン水溶液及びその製造法
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
DE3650772T2 (de) 1985-04-27 2003-04-03 Hoffmann La Roche Derivate von Indazole-3-carboxamide und -3-carboxylsäure
US5240954A (en) 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) 1989-06-28 1989-08-16 Glaxo Group Ltd Process
HU218654B (hu) * 1989-11-28 2000-10-28 Syntex (U.S.A.) Inc. Triciklusos vegyületek, ezeket hatóanyagként tartalmazó gyógyászati készítmények és eljárás előállításukra
ES2149305T3 (es) 1991-05-03 2000-11-01 Searle & Co Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso.
US5272137A (en) 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5567818A (en) * 1994-07-08 1996-10-22 Syntex (U.S.A.) Inc. Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein
GB9423588D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
JP3845902B2 (ja) * 1996-07-09 2006-11-15 ソニー株式会社 磁気記録再生装置
ATA156496A (de) 1996-09-03 1997-10-15 Nycomed Austria Gmbh Pharmazeutische zusammensetzung
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US20030095926A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US6294548B1 (en) 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
DE19833119A1 (de) 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
WO2000024375A1 (en) * 1998-10-27 2000-05-04 Alcon Laboratories, Inc. Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
RU2003121304A (ru) 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
CN1525856A (zh) 2001-05-11 2004-09-01 三菱制药株式会社 含吡唑啉酮衍生物的稳定的高浓度注射剂
WO2003100091A1 (en) 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Means and methods for improved treatment using 'setrones'
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
US7109339B2 (en) 2002-12-19 2006-09-19 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
ES2285407T3 (es) 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting

Also Published As

Publication number Publication date
MA27710A1 (fr) 2006-01-02
HRP20050676B1 (hr) 2013-02-28
NO329500B1 (no) 2010-11-01
US9457020B2 (en) 2016-10-04
IL169859A (en) 2014-11-30
US7960424B2 (en) 2011-06-14
DK1601359T3 (da) 2009-01-05
GEP20084445B (en) 2008-08-10
AU2004208505B2 (en) 2009-09-03
CA2573241A1 (en) 2004-08-12
UA90449C2 (ru) 2010-05-11
IS7984A (is) 2005-08-15
ES2315635T3 (es) 2009-04-01
JP5461763B2 (ja) 2014-04-02
CY1108660T1 (el) 2014-04-09
EP1601359B1 (de) 2008-10-08
JO2735B1 (en) 2013-09-15
JP2006516583A (ja) 2006-07-06
AU2004208505C1 (en) 2015-10-01
CR7921A (es) 2006-02-07
PT1601359E (pt) 2008-11-03
CA2514224C (en) 2009-11-03
CA2573194A1 (en) 2004-08-12
BRPI0407121A (pt) 2006-01-10
ZA200506917B (en) 2006-08-30
JP5551658B2 (ja) 2014-07-16
BRPI0407121B8 (pt) 2021-06-29
JP2011236242A (ja) 2011-11-24
KR20050104363A (ko) 2005-11-02
US20140039000A1 (en) 2014-02-06
EA014066B1 (ru) 2010-08-30
US20060167073A1 (en) 2006-07-27
US20130267553A1 (en) 2013-10-10
PL378398A1 (pl) 2006-04-03
US20060069114A1 (en) 2006-03-30
UY28175A1 (es) 2004-09-30
TWI342212B (en) 2011-05-21
BRPI0407121B1 (pt) 2018-07-17
CA2573363A1 (en) 2004-08-12
US9308266B2 (en) 2016-04-12
AU2004208505A2 (en) 2004-08-12
KR101113084B1 (ko) 2012-02-15
US20060167071A1 (en) 2006-07-27
PA8594801A1 (es) 2004-09-16
AR042977A1 (es) 2005-07-13
HRP20050676A2 (en) 2005-10-31
TNSN05180A1 (en) 2007-06-11
US7947725B2 (en) 2011-05-24
ECSP055938A (es) 2006-03-01
TW200418517A (en) 2004-10-01
CN1758911A (zh) 2006-04-12
PE20050066A1 (es) 2005-04-20
CA2514224A1 (en) 2004-08-12
AP2005003382A0 (en) 2005-09-30
EP2008659A1 (de) 2008-12-31
AU2004208505A1 (en) 2004-08-12
NZ541533A (en) 2008-12-24
MXPA05008028A (es) 2006-01-27
DE602004016967D1 (de) 2008-11-20
US8518981B2 (en) 2013-08-27
US20160000773A1 (en) 2016-01-07
SI1601359T1 (sl) 2009-04-30
EA200501203A1 (ru) 2006-06-30
AP2110A (en) 2010-03-01
HK1076401A1 (en) 2006-01-20
EP1601359A1 (de) 2005-12-07
US8598218B2 (en) 2013-12-03
MY144036A (en) 2011-07-29
US20110192493A1 (en) 2011-08-11
US20160317440A1 (en) 2016-11-03
CN102813621A (zh) 2012-12-12
US20140097114A1 (en) 2014-04-10
NO20053987L (no) 2005-08-26
US7947724B2 (en) 2011-05-24
CA2573228A1 (en) 2004-08-12
WO2004067005A1 (en) 2004-08-12
RS20050578A (en) 2007-09-21

Similar Documents

Publication Publication Date Title
NO20053987L (no) Flytende farmasoytiske palonosetronformuleringer
ATE334656T1 (de) Flüssige pharmazeutische zusammensetzung
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
PT1501534E (pt) Formulacoes farmaceuticas
NO20033384D0 (no) Farmasöytisk formulering
ATE460169T1 (de) Pharmazeutische formulierung mit lanthanum- verbindungen
ITTO20010008A0 (it) Formulazione farmaceutica
NO20033556L (no) Farmasöytiske formuleringer
DE60307677D1 (de) Dispergierbare pharmazeutische zusammensetzungen
DE60111769D1 (de) Flüssige pharmazeutische formulierungen mit verbesserter oraler veträglichkeit
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
NO20035627D0 (no) Farmasöytisk formulering
GB0316206D0 (en) Pharmaceutical formulation
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
DE10107261B4 (de) Pharmazeutische Zusammensetzung
DE112004001429D2 (de) Pharmazeutischer Wirkstoff
NO20041236L (no) Farmasoytisk formulering
DE602004030921D1 (de) Pharmazeutische zusammensetzung
SE0200449D0 (sv) Pharmaceutical formulation
SE0201660D0 (sv) Pharmaceutical formulation
GB0310881D0 (en) Pharmaceutical formulation
SE0103565D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1601359

Country of ref document: EP